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Objectives
HIV treatment guidelines endorse switching or simplification of antiretroviral therapy in
therapy-experienced patients with suppressed viraemia; ritonavir discontinuation may also
enhance tolerability and reduce long-term adverse events (AEs). This open-label, multicentre,
noninferiority study enrolled HIV-1-infected, treatment-experienced adults with confirmed HIV-1
RNA ≤ 75 HIV-1 RNA copies/mL currently receiving tenofovir/emtricitabine + atazanavir/ritonavir
(TDF/FTC + ATV/r) for ≥ 6 months with no reported history of virological failure.
Methods
Participants were randomized 1:2 to continue current treatment or switch to abacavir/lamivudine
+ atazanavir (ABC/3TC + ATV). Endpoints included the proportion of participants with HIV-1
RNA < 50 copies/mL by time to loss of virological response (TLOVR), AEs, fasting lipids, and
inflammatory, coagulation, bone and renal biomarkers.
Results
After 48 weeks, 76% (152 of 199) of ABC/3TC + ATV-treated and 79% (77 of 97)
of TDF/FTC + ATV/r-treated participants had HIV-1 RNA < 50 copies/mL (TLOVR;
P = 0.564). Other efficacy analyses yielded similar results. Rates of new grade 2–4 AEs were
45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment-
emergent grade 3–4 laboratory abnormalities higher with TDF/FTC + ATV/r (36%) compared
with ABC/3TC + ATV (19%). Most fasting lipid levels remained stable over time; high-density
lipoprotein (HDL) cholesterol increased modestly in ABC/3TC + ATV-treated participants. Bone
and renal biomarkers improved significantly between baseline and week 48 in participants
taking ABC/3TC + ATV and were stable in participants taking TDF/FTC + ATV/r. No significant
changes occurred in any inflammatory or coagulation biomarker within or between treatment
groups.
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Francisco, CA and the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 10–13 September 2013 in Denver, CO. The interim study
results (24-week analysis) were published in PLoS ONE in 2014 [15].
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Conclusions
The ABC/3TC + ATV treatment-switch group had similar viral suppression rates up to 48 weeks
to the TDF/FTC + ATV/r comparator group, with lower rates of moderate- to high-grade
hyperbilirubinaemia and improvements in bone and renal biomarkers.
Keywords: abacavir, bone biomarkers, HIV, renal biomarker, tenofovir
Accepted 14 April 2014
Introduction
HIV treatment guidelines from the US Department of Health
and Human Services (DHHS) have endorsed regimen sim-
plification or switching in treatment-experienced patients
with suppressed viraemia [1]. One simplification strategy is
the discontinuation of low-dose ritonavir once viral sup-
pression has been achieved, which has been shown in some
studies to improve tolerability and reduce toxicities [2–9].
Depending on the other regimen components, ritonavir
discontinuation may also eliminate concern about
cytochrome P4503A (CYP3A)-mediated drug interactions
with other drugs [2–10]. While atazanavir is a generally
well-tolerated protease inhibitor (PI) whose plasma concen-
tration and genetic barrier to resistance are improved
by coadministration with ritonavir, the combination is
also associated with an increased risk of indirect
hyperbilirubinaemia [11–13], which, when accompanied by
scleral icterus, can prompt treatment discontinuation [14].
This study, ASSURE (A Simplification Study of Unboosted
Reyataz with Epzicom), investigated the efficacy and safety
of discontinuing ritonavir in virologically suppressed par-
ticipants receiving a regimen of tenofovir/emtricitabine +
atazanavir/ritonavir (TDF/FTC + ATV/r), one of the recom-
mended first-line regimens in the DHHS guidelines [1]. As
TDF/FTC is not recommended for use with unboosted ATV
because of a drug – drug interaction that results in decreased
concentrations of ATV [11], participants in this trial who
were randomized to discontinue ritonavir simultaneously
switched to a nucleoside reverse transcriptase inhibitor
(NRTI) backbone of abacavir/lamivudine (ABC/3TC). This
paper presents the 48-week results of this study, including
virological efficacy, immunological response, safety, toler-
ability, and HIV-1 genotypic and phenotypic resistance
patterns in participants who experienced confirmed viro-
logical failure. Changes from baseline in fasting lipids and in
biomarkers associated with cardiovascular, bone and renal
health were also evaluated.
Methods
The prospective, randomized, multicentre, open-label, phase
IV ASSURE study (EPZ113734; NCT01102972) enrolled HIV-
1-infected, antiretroviral (ART)-experienced adults (≥18
years of age) who were receiving a once-daily regimen of
TDF/FTC (300 mg/200 mg) + ATV/r (300 mg/100 mg) for at
least 6 months prior to the first day of screening. Eligible
participants were virologically suppressed (defined as HIV-1
RNA ≤ 75 HIV-1 RNA copies/mL) at two consecutive time-
points (including the screening visit and one additional visit
at least 28 days prior to screening). TDF/FTC + ATV/r could
be a participant’s initial regimen or first or second switch
regimen (defined as any change in ART components) as long
as there was no documented history of virological failure.
All previous ART regimens consisted of two NRTIs (either
TDF/FTC or zidovudine/lamivudine) plus either a Food and
Drug Administration (FDA)-licensed nonnucleoside reverse
transcriptase inhibitor (NNRTI) or a ritonavir-boosted PI,
although alternative prior regimens were allowed on a
case-by-case basis.
Participants were excluded if they were human leucocyte
antigen (HLA)-B*5701-positive, or had prior abacavir expo-
sure, active Centers for Disease Control and Prevention
(CDC) clinical category C disease, ongoing clinically relevant
hepatitis and/or chronic hepatitis B virus (HBV) infection
[HBV surface antigen positive (HBsAg+)] or a creatinine
clearanc < 50 mL/min via the Cockroft – Gault method. While
a baseline genotype was not required, participants were
deemed ineligible if they had known HIV genotyping results
that indicated the presence of any NRTI or PI mutation
associated with resistance to any study drug. There were no
CD4 cell count restrictions. Women of child-bearing potential
were eligible if they had negative pregnancy tests at screening
and baseline and agreed to use protocol-prescribed contracep-
tion methods throughout the study. Additional information on
inclusion/exclusion criteria, including a link to the study
protocol, is available in a previous publication [15]. All par-
ticipants provided written informed consent to participate in
the study, and the protocol was approved by the institutional
review board for each study site.
Design and intervention
After stratification by prior ART experience (TDF/
FTC + ATV/r as initial regimen or as first/second switch
regimen), eligible participants were randomized 2:1 to sim-
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plify their regimen to once-daily ABC/3TC 600 mg/300 mg
(ViiV Healthcare, Research Triangle Park, NC) plus 400 mg
ATV once daily (two 200 mg tablets; Bristol-Myers Squibb,
Princeton, NJ) or to remain on once-daily TDF/FTC (Gilead
Sciences, Foster City, CA) plus one 300 mg ATV tablet
boosted with a 100 mg ritonavir tablet (AbbVie, Chicago,
IL). Randomization and study drug provisioning were per-
formed by GlaxoSmithKline’s randomization and medica-
tion ordering system.
Procedures and assessments
Participants were evaluated at screening, baseline, and
weeks 2, 4, 12, 24, 36 and 48; visits included routine
chemistry, haematology, HIV-1 RNA and immunology
assessments. The concentrations of specific biomarkers
[bone alkaline phosphatase (BAP), parathyroid hormone
(PTH), C-terminal telopeptide (C-telopeptide), osteocalcin,
urine β2 microglobulin (β2m):creatinine ratio, high-
sensitivity C-reactive protein (hs-CRP), interleukin-6 and
D-dimer] were evaluated at baseline, week 24 and week 48
(as were vitamin D levels).
HIV-1 RNA concentrations were measured using the
RealTime HIV-1 Assay (Abbott Molecular, Inc., Des Plaines,
IL). Adverse events and laboratory toxicities were graded
using the 2004 Division of AIDS Toxicity Grading Scale.
All suspected ABC hypersensitivity events were reported as
serious adverse events (SAEs). Glomerular filtration rates
(GFRs) were estimated using the modification of diet in
renal disease (MDRD) formula [16]. Smoking status and
presence of diabetes were assessed at baseline, week 24 and
week 48 for Framingham risk score calculation [17];
treatment-emergent changes in fasting total, high-density
lipoprotein (HDL) and low-density lipoprotein (LDL) cho-
lesterol and triglycerides were assessed using the Division
of AIDS lipid toxicity grading system [18]. Viral genotypes
and phenotypes were determined by Monogram
Biosciences (South San Francisco, CA); mutations were
defined according to International AIDS Society–USA
Guidelines [19]. All other laboratory tests were performed
centrally by Quest Diagnostics (Van Nuys, CA).
Study populations
The intent-to-treat (ITT) population consisted of all
enrolled participants randomized in the study. The primary
population for efficacy analyses included all participants in
the ITT population who received at least one dose of study
drug [ITT-exposed (ITT-E)]. The safety population consisted
of all randomized participants who consumed any inves-
tigational product. The virological failure population
included all participants who met the protocol-defined
criteria for confirmed virological failure, defined as plasma
HIV-1 RNA ≥ 400 copies/mL on two consecutive occasions.
The observed data set contained all data collected while
participants were in the study; no missing values were
imputed.
Outcome measures
The primary efficacy endpoint was the proportion of par-
ticipants with HIV-1 RNA < 50 copies/mL at week 24 by the
time to loss of virological response (TLOVR) algorithm [15].
The proportion of participants with HIV-1 RNA < 50
copies/mL at week 48 was a secondary endpoint. Other
secondary endpoints included the proportion of partici-
pants with HIV-1 RNA < 400 copies/mL, the change from
baseline in CD4 cell count, time to virological failure,
detection of genotypic and phenotypic resistance at the
time of virological failure, change from baseline in fasting
lipid profiles (total, LDL and HDL cholesterol and
triglycerides), grade 2–4 AEs and all SAEs. There were two
exploratory endpoints: (1) change from baseline in
neurocognition scores, to be reported in a separate paper;
and (2) change from baseline in eight cardiovascular/
inflammation, bone and renal biomarkers, included in this
publication.
Statistical analyses
Per protocol, virological response rates at week 48 were
compared using a Cochran – Mantel−Haenszel test strati-
fied by initial ART regimen (TDF/FTC + ATV/r as initial
regimen or as first/second switch regimen). All statistical
comparisons were based on a two-sided significance level of
0.05. Continuous variables were assessed using the
Wilcoxon rank-sum test, and binary responses were com-
pared using Fisher’s exact test. Biomarker data were log-
transformed prior to analysis, and the change from baseline
was assessed using geometric mean ratios with 95% confi-
dence intervals. The statistical analyses were performed
using SAS Version 9.1 (SAS Institute Inc., Cary, NC).
Results
Characteristics and accountability
This study enrolled 297 participants from 43 clinical sites
in the USA and Puerto Rico. One participant randomized to
TDF/FTC + ATV/r was withdrawn because of a protocol
violation prior to receiving any study medication, so the
ITT-E population included 199 participants simplifying to
ABC/3TC + ATV and 97 continuing on TDF/FTC + ATV/r.
Participants were recruited between April 2010 and Decem-
ber 2011, and the last 48-week analysis visit occurred in
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December 2012. Most participants (79%) were male
(Table 1), 34% were of African-American/African heritage,
and 26% self-identified as Hispanic/Latino. The median
baseline CD4 cell count was 492 cells/μL. Median time on
ART prior to enrolment was 978 days for the ABC/
3TC + ATV group and 1106 days for the TDF/FTC + ATV/r
group.
Eighty-five per cent (253) of participants in the ITT-E
population completed 48 weeks on study (Fig. 1). The most
common reasons for study withdrawal were lost to
follow-up (5%; 15 participants), consent withdrawn (4%;
12 participants), and AEs (3%; 10 participants).
Efficacy results
As previously reported [15], 86.9% (173 of 199) of partici-
pants in the ABC/3TC + ATV treatment group successfully
maintained HIV-1 RNA < 50 copies/mL by the TLOVR
analysis at week 24 compared with 86.6% (84 of 97) in the
TDF/FTC + ATV/r group. The adjusted treatment difference
was 0.33%, and the two-sided 95% confidence interval (CI)
(−7.97 to 8.64%) stratified by prior ART regimen excluded
the predefined noninferiority margin of −12%, demonstrat-
ing the noninferiority of the ABC/3TC + ATV simplification
regimen to the TDF/FTC + ATV/r continuation regimen.
At week 48, the efficacy results were also similar between
treatment groups (P = 0.564), with 76% (152 of 199) of
participants taking ABC/3TC + ATV and 79% (77 of 97)
taking TDF/FTC + ATV/r having HIV-1 RNA < 50 copies/mL
by TLOVR analysis. In the observed analysis, there was no
significant difference (P = 0.134) in HIV-1 RNA < 50
copies/mL at week 48 between treatment groups, with
response rates of 91% (154 of 169) in the ABC/3TC + ATV-
treated group versus 96% (79 of 82) in the TDF/FTC + ATV/
r-treated group. There was no significant difference between
treatment groups by TLOVR analysis in the HIV-1 RNA < 50
copies/mL response rate when adjusted by gender
(P = 0.672), race (P = 0.645) or age (P = 0.652).
At week 48, median CD4 cell counts were 603 and 590
cells/μL for ABC/3TC + ATV and TDF/FTC + ATV/r, respec-
tively. However, the median increase in CD4 cell count
from baseline to week 48 was significantly larger
(P = 0.026) in the ABC/3TC + ATV group (+90 cells/μL)
compared with the TDF/FTC + ATV/r group (+47 cells/μL).
Virology results
Confirmed virological failure occurred in four of 199 (2%)
participants switched to ABC/3TC + ATV and one of 97
(1%) participants continuing on TDF/FTC + ATV/r. At viro-
logical failure, HIV-1 from three participants (two receiving
ABC/3TC + ATV; one receiving TDF/FTC + ATV/r) was fully
susceptible to all drugs, with no reverse transcriptase (RT)
mutations and a few minor PI mutations (including L10I,
G16G/E, D60E, I62V, V77I and I93L) detected, and con-
firmed virological failure was associated with site reports
of noncompliance and/or therapy interruption. HIV-1 from
the remaining two participants had reduced study drug
susceptibility at failure. One ABC/3TC + ATV-receiving
participant experienced initial rebound at day 14, con-




(n = 97) Total
Age (years) [median (range)] 44 (21–66) 42 (20–68) 43.5 (20–68)
Male [n (%)] 155 (78) 79 (81) 234 (79)
Race [n (%)]
African-American/African heritage 65 (33) 37 (38) 102 (34)
White/Caucasian/European heritage 122 (61) 55 (57) 177 (60)
Other 12 (6) 5 (5) 17 (6)
Hispanic or Latino ethnicity [n (%)] 51 (26) 26 (27) 77 (26)
Plasma HIV-1 RNA (log10 copies/mL) (median) 1.59 1.59 1.59
<50 copies/mL [n (%)] 192 (96) 93 (96) 285 (96)
50 to 74 copies/mL [n (%)] 2 (1) 2 (2) 4 (1)
≥ 75 copies/mL [n (%)] 5 (3) 2 (2) 7 (2)
CD4 cell count (cells/μL) [median (range)] 492 (77–1196) 480 (108–1479) 292 (77–1479)
<200 cells/μL [n (%)] 14 (7) 6 (6) 20 (7)
CDC HIV infection classification [n (%)]
Category A 136 (68) 67 (69) 203 (69)
Category B 26 (13) 13 (13) 39 (13)
Category C 37 (19) 17 (18) 54 (18)
Hepatitis C virus coinfection [n (%)] 18 (9) 8 (8) 26 (9)
Time on prior ART (days) [median (range)] 978 (177–4830) 1106 (199–7078) 998 (177–7078)
ABC/3TC, abacavir/lamivudine; ART, antiretroviral therapy; ATV, atazanavir; ATV/r, atazanavir/ritonavir; CDC, Centers for Disease Control and Prevention;
TDF/FTC, tenofovir/emtricitabine.
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comitant with site-reported treatment compliance issues.
No prior HIV-1 genotypes or comprehensive treatment
records were available, but the participant reported receiv-
ing nevirapine plus TDF/FTC for >8 years before TDF/
FTC + ATV/r. Numerous HIV-1 RT mutations (M41L, L74V,
K103N, M184V, L210W and T215Y) were detected, includ-
ing thymidine analogue mutations (TAMs), despite no prior
reported zidovudine- or stavudine-containing treatment.
Multiple PI mutations (L10F, K20I, M46I, I54V, I62V, L63P,
A71T, G73T, I84V and L90M) were detected. The partic-
ipant’s HIV-1 had reduced phenotypic susceptibility to
multiple drugs, including ABC, 3TC and ATV. The final
ABC/3TC + ATV-receiving participant experienced viral
rebound at week 36. No prior genotypes were available.
Several years of prior treatment with TDF/FTC and
efavirenz before switching to a TDF/FTC + ATV/r regimen
were reported. The M41L and T215Y TAMs and the M184V
mutation were detected at failure, despite no prior reported
zidovudine or stavudine treatment, as were numerous PI
mutations (L10I, K20R, L24I, M36I, K43T, M46L, I62V,
V82A and L89M); the virus from this participant remained
susceptible to both ABC and TDF but had reduced suscep-
tibility to ATV and 3TC/FTC.
Safety and tolerability results
Rates of AEs of moderate or greater severity (grade 2–4)
were similar between the two groups (45% for both groups;
Table 2). There were few grade 2–4 treatment-related AEs
in either group (9% for ABC/3TC + ATV and 6% for TDF/
FTC + ATV/r). Five participants experienced grade 2–4
cardiac disorders during the course of the study; none were
considered to be drug related. In the TDF/FTC + ATV/r
group, one participant had grade 2 palpitations. In the
ABC/3TC + ATV group, two participants were diagnosed
with grade 2 cardiomyopathy; the third had a prior history
of congestive heart failure and developed grade 2 coronary
artery disease, and the fourth participant, a former smoker
Fig. 1 Participant disposition. Primary reasons for withdrawal were listed by the investigator on the case report form. aAll adverse events leading
to study discontinuation were grade 1 or 2, with the exception of a grade 3 lipase increase in one participant continuing on tenofovir/
emtricitabine + atazanavir/ritonavir (TDF/FTC + ATV/r). ABC/3TC, abacavir/lamivudine; ATV, atazanavir; ATV/r, atazanavir/ritonavir; TDF/FTC, tenofovir/
emtricitabine.
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with diabetes, hyperlipidaemia, and a family history of
cardiovascular disease, had a grade 4 acute inferior myo-
cardial infarction.
Adverse events leading to study withdrawal affected 4%
of participants receiving ABC/3TC + ATV and 2% of par-
ticipants continuing on TDF/FTC + ATV/r; of these, only
nausea, vomiting and rash were reported in more than one
participant. Suspected ABC hypersensitivity was reported
for one participant during the course of the study; the
participant was not withdrawn but restarted his original
TDF/FTC + ATV/r regimen with resolution of signs and
symptoms.
The rate of treatment-emergent or worsening grade 2–4
(P = 0.0026) and grade 3–4 (P = 0.0014) laboratory abnor-
malities was significantly higher in the TDF/FTC + ATV/r
group compared with the ABC/3TC + ATV group. The dif-
ference was primarily driven by change from baseline in
total bilirubin levels. Other treatment-emergent grade 3–4
laboratory abnormalities were infrequent and similar
between groups (Table 2). The fasting lipid levels for par-
ticipants with paired baseline and week 48 results (Fig. 2)
were similar between treatment groups and varied little
between baseline and week 48, except for a small but
statistically significant increase in median HDL cholesterol
levels (3.0 mg/dL; P = 0.013) for the ABC/3TC + ATV group.
At baseline, the median estimated glomerular filtration
rate by the MDRD equation was 93 mL/min/1.73 m2 for
both treatment groups. At week 48, there was a small
median increase of 0.8 mL/min/1.73 m2 for the ABC/
3TC + ATV group and a small median decrease of −1.3 mL/
min/1.73 m2 in the TDF/FTC + ATV/r group, but this effect
was not statistically significant.
Table 2 Adverse events and laboratory abnormalities
ABC/3TC + ATV
(n = 199) n (%)
TDF/FTC + ATV/r
(n = 97) n (%)
Grade 2−4 AEs
Any 90 (45) 44 (45)
Occurring in ≥ 5% of participants in either treatment group
Upper respiratory tract infection 11 (6) 7 (7)
Treatment related† 17 (9) 6 (6)
Nausea 4 (2) 0
Abnormal dreams 2 (1) 0
Dizziness 2 (1) 0
Severe or grade 3−4 AEs
Any‡ 29 (15) 10 (10)
Treatment related 0 2 (2)
Blood bilirubin increased 0 1 (1)
Lipase increased 0 1 (1)
Serious AEs
Any‡ 21 (11) 6 (6)
Treatment related 1 (< 1) 0
Drug hypersensitivity 1 (< 1) 0
AEs leading to study withdrawal
Any 8 (4) 2 (2)
AEs occurring in > 1 participant and leading to study withdrawal
Nausea 3 (2) 0
Vomiting 2 (1) 0
Rash 2 (1) 0
Treatment-emergent laboratory abnormalities
Any grade 2 − 4 event§ 99 (50) 66 (69)
Any grade 3 − 4 event¶ 37 (19) 35 (36)
Total bilirubin 12 (6) 28 (29)
Creatine kinase 7 (4) 4 (4)
Lipase 5 (3) 3 (3)
Inorganic phosphorus 5 (3) 1 (1)
Glucose 5 (3) 1 (1)
LDL cholesterol calculation 3 (2) 2 (2)
Aspartate aminotransferase 1 (< 1) 1 (1)
Alanine aminotransferase 1 (< 1) 1 (1)
Cholesterol 1 (< 1) 0
†Listing includes all events occurring in more than one participant.
‡No single event occurred in more than three participants.
§P = 0.0026 using Fisher’s exact test.
¶P = 0.0014 using Fisher’s exact test.
ABC/3TC, abacavir/lamivudine; AE, adverse event; ATV, atazanavir; ATV/r, atazanavir/ritonavir; LDL, low-density lipoprotein; TDF/FTC, tenofovir/emtricitabine.
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The median 10-year risk of coronary heart disease as
measured by the Framingham equation at baseline and
week 48 was 2.0% and 2.0%, respectively, for the ABC/
3TC + ATV group and 1.5% and 2.0% for the TDF/
FTC + ATV/r group, respectively.
Biomarkers
Between baseline and week 48, there was a significant
(P < 0.001) decrease resulting in improvement for the
measured bone biomarkers BAP, PTH, C-telopeptide and
osteocalcin in the ABC/3TC + ATV group (Fig. 3a–d); these
biomarkers remained relatively unchanged in the TDF/
FTC + ATV/r group over the same time period. Comparing
the two treatment groups, the decrease from baseline to
week 48 in all four of these bone biomarkers was signifi-
cantly larger (P < 0.001) for the ABC/3TC + ATV group than
for the TDF/FTC + ATV/r group. Serum calcium levels
remained similar within and between groups, with baseline
mean values of 9.33 and 9.35 mg/dL for the ABC/
3TC + ATV and TDF/FTC + ATV/r groups, respectively, and
mean changes of 0.05 and −0.02 mg/dL, respectively, at
week 48. Vitamin D (25 OH) geometric mean values were in
the low but normal range at baseline (28.3 ng/mL in the
ABC/3TC + ATV group and 26.4 ng/mL in the TDF/
FTC + ATV/r group). At week 48, these values were
24.6 ng/mL in the ABC/3TC + ATV group and 29.3 ng/mL
in the TDF/FTC + ATV/r group, representing a decline from
baseline for the ABC/3TC + ATV group (P < 0.001) and an
increase for the TDF/FTC + ATV/r group (P = 0.005).
The renal biomarker β2M:creatinine ratio declined by
56% in the ABC/3TC + ATV group (P < 0.001) but increased
by 14% in the TDF/FTC + ATV/r group (Fig. 3e); the change
from baseline to week 48 was significantly different
(P < 0.001) between treatment groups.
Conversely, there were no significant changes from base-
line to week 48 in any of the biomarkers associated with
cardiovascular disease, inflammation or thrombogenesis
that were evaluated (hs-CRP, interleukin-6 and D-dimer)
either within or between treatment groups (Fig. 3f−h).
Discussion
In this randomized, multicentre ASSURE study, the propor-
tion of participants maintaining suppression of HIV-1
RNA < 50 copies/mL by TLOVR at week 48 was similar
between participants switching to ABC/3TC + ATV (76%)
and those maintaining on TDF/FTC + ATV/r (79%). The
Fig. 2 Median fasting lipid parameters with guideline cut-offs from the National Cholesterol Education Program (NCEP) [17] for participants with
paired baseline and week 48 values. A significant increase (P < 0.0001) in median high-density lipoprotein (HDL) cholesterol levels for the change
from baseline (CFB) to week 48 was seen for the abacavir/lamivudine + atazanavir (ABC/3TC + ATV) group with no significant increase in the
tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC + ATV/r) treatment group (P = 0.8994); a significant difference (P = 0.013) between treatment
groups was also observed. ABC/3TC, abacavir/lamivudine; ATV, atazanavir; ATV/r, atazanavir/ritonavir; LDL, low-density lipoprotein; TDF/FTC,
tenofovir/emtricitabine.
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efficacy and tolerability of ABC/3TC + ATV demonstrated
in this study complement those observed in the ARIES trial,
where ART-naïve patients initiated treatment with ABC/
3 TC + ATV/r, and after 36 weeks the virologically sup-
pressed population was randomized to continue on the
same regimen or switch to a regimen of ABC/3TC + ATV.
Viral suppression was maintained 48 weeks post-
randomization in 86% of patients in the ABC/3TC + ATV-
treated group and in 81% of those taking ABC/
3TC + ATV/r, accompanied by lower rates of treatment-
related grade 2 − 4 AEs and a decrease in
hyperbilirubinaemia from 14% to 4% for the ABC/
3TC + ATV-treated group [9]. In ASSURE, switching to
ABC/3TC + ATV was also accompanied by fewer treatment-
emergent or worsening AEs, driven largely by a lower rate
of moderate to severe hyperbilirubinaemia and by a modest
but significant increase in median CD4 cell count. Simi-
larly, in the INDUMA study, previously antiretroviral-naïve
patients received two NRTIs plus ATV/r for 26 to 30 weeks,
and virologically suppressed patients were randomized to
unboosted ATV or maintained ATV/r. After 48 weeks there
was no significant difference in virological suppression
between the groups (78% for ATV and 75% for ATV/r),
while hyperbilirubinaemia decreased by 50% (from 32 to
16%) in the unboosted ATV group [4].
In the ASSURE study, significant improvements in the
bone turnover markers PTH, BAP, C-telopeptide and
osteocalcin were observed following the switch to ABC/
3TC + ATV, with little change over time in the TDF/
FTC + ATV/r group. Initiation of ART is often associated
with decreases in bone mineral density that slow or stabi-
lize over 24 to 48 weeks of therapy; these losses tend to be
larger with TDF-containing regimens compared with non-
TDF-containing regimens [20–23]. Bone biomarkers have
been studied in treatment-naïve patients initiating therapy
[24–27], but few randomized trials have included
treatment-experienced adults [28–30]; results from these
treatment-experienced studies were generally consistent
with our findings that bone biomarkers were more favour-
able in patients taking ABC/3TC compared with TDF/FTC
and probably reflect clinically relevant differences between
these regimens in bone turnover. The improvement in bone
markers observed after switching from TDF in our study
was not explained by changes in levels of calcium or
vitamin D. Vitamin D levels at baseline and at week 48
remained within the lower end of the normal range for
both treatment groups, and a small decline was noted for
these levels in the ABC/3TC + ATV treatment group.
Switching to ABC/3TC + ATV also resulted in improve-
ment in the β2M:creatinine ratio, a validated marker of
combined glomerular and tubular health. While the asso-
ciation between TDF and renal impairment is well studied
(for example [31–34],), only one randomized trial, ASSERT,
which compared ABC/3TC with TDF/FTC both in combina-
tion with efavirenz in treatment-naïve patients, has
included the β2M:creatinine ratio [32]. After 48 weeks on
therapy, the β2M:creatinine ratio increased by 24% in the
TDF/FTC group and decreased by 47% in the ABC/3TC
group (P < 0.0001), a result consistent with the results
observed in ASSURE (albeit in treatment-naïve patients).
In this study, switching to ABC/3TC + ATV was not asso-
ciated with significant changes in the markers of inflam-
mation and coagulation, interleukin-6, hs-CRP and
D-dimer. Data regarding these markers following adminis-
tration of ABC have been mixed. Several studies found no
increase in markers of cardiovascular disease with initia-
tion of ABC compared with other NRTIs [28,29,34–39],
while study A5202 reported a significant increase from
baseline in hs-CRP after 96 weeks in treatment-naïve
patients randomized to ABC/3TC, with no significant
change in patients randomized to TDF/FTC, although
interleukin-6 levels decreased significantly in both the
ABC/3TC- and TDF/FTC-treated groups [24]. Four other
studies have examined cardiovascular markers in
treatment-experienced patients: STEAL [28], SWAP [29],
BICOMBO [36], and SWIFT [40]. As in our study, none of
these trials reported a difference between ABC/3TC and
TDF/FTC in hs-CRP, interleukin-6 or D-dimer over 48 weeks
of post-randomization treatment.
Virological failure was rare in both study arms. Wild-
type virus at virological failure was detected in three of five
participants with confirmed viraemia > 400 copies/mL and
was associated with therapy interruption/noncompliance.
Two additional participants, both receiving ABC/
3TC + ATV, experienced virological failure, one shortly
after therapy switch (day 14) and one at week 36. Multiple
viral resistance mutations, including TAMs, were detected
in virus from both participants, and the K103N NNRTI
mutation was detected in one participant. As TAMS are not
selected by treatment with either TDF/FTC or ABC/3TC,
these results are suggestive of these participants having
previously experienced treatment failure on either
zidovudine- or stavudine-containing regimens, although
no prior exposure was reported for either participant.
There are several limitations of this trial that should be
considered when interpreting results from this study. This
simplification treatment strategy is restricted to certain
NRTI backbones such as ABC/3TC that can be used in
combination with unboosted ATV. The study enrolled
virologically suppressed, therapy-experienced patients and
was designed to exclude those patients with prior virologi-
cal failure that could have resulted in selection for drug
resistance-associated viral mutations affecting resistance
to the investigational products. Therefore, extrapolating
© 2015 British HIV Association HIV Medicine (2016), 17, 106--117
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these findings to other patient populations may be inap-
propriate. Plasma concentrations of ATV in the absence of
ritonavir boosting are lower, and therefore this regimen
may be more susceptible to patient adherence issues, espe-
cially if archived resistance-associated mutations are
present. While the markers of bone density examined are
considered accepted markers of bone turnover, this study
did not directly measure bone density.
Conclusions
Over 48 weeks, discontinuation of ritonavir after switching
from a regimen of TDF/FTC + ATV/r to ABC/3TC + ATV
maintained viral suppression in study participants and led
to improvements in CD4 cell count, the bone biomarkers
PTH, BAP, C-telopeptide and osteocalcin, and the renal
β2M:creatinine ratio. The ABC/3TC + ATV treatment group
also had significantly fewer laboratory abnormalities than
the TDF/FTC + ATV/r treatment group without increasing
other fasting lipid levels or cardiovascular biomarkers of
inflammation and thrombogenesis.
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